Last reviewed · How we verify
instillation of NOV03
instillation of NOV03 is a Small molecule drug developed by Bausch & Lomb Incorporated. It is currently FDA-approved.
At a glance
| Generic name | instillation of NOV03 |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of NOV03 on the Tear Film (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- instillation of NOV03 CI brief — competitive landscape report
- instillation of NOV03 updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about instillation of NOV03
What is instillation of NOV03?
instillation of NOV03 is a Small molecule drug developed by Bausch & Lomb Incorporated.
Who makes instillation of NOV03?
instillation of NOV03 is developed and marketed by Bausch & Lomb Incorporated (see full Bausch & Lomb Incorporated pipeline at /company/bausch-lomb-incorporated).
What development phase is instillation of NOV03 in?
instillation of NOV03 is FDA-approved (marketed).
Related
- Manufacturer: Bausch & Lomb Incorporated — full pipeline
- Compare: instillation of NOV03 vs similar drugs
- Pricing: instillation of NOV03 cost, discount & access